The Institute for Clinical and Economic Review (ICER) says upcoming reports will focus on the comparative clinical effectiveness and value of high-risk prostate cancer and hereditary amyloidosis treatments.
According to a press release, the reports will be reviewed during the September meeting of the Midwest Comparative Effectiveness Public Advisory Council.
The review of prostate cancer treatments will include assessments of the following three anti-androgen drugs:
- Enzalutamide (Xtandi, Astellas and Medivation);
- Abiraterone acetate (Zytiga, Janssen); and
- Apalutamide (Erleada, Janssen).
The second report will focus on two new therapies for hereditary transthyretin-related amyloidosis:
- Inotersen (Ionis Pharmaceuticals, Inc.); and
- Patisiran (Alnylam Pharmaceuticals).
Comments will be accepted during an Open Input period which began Friday, and is scheduled to end 5 p.m. March 7.
More information about ICER’s input period can be found by clicking here.
